Protein in urine may point to more sensitive screening tests for women with ovarian cancer

	Tweet

According to the National Cancer Institute, ovarian cancer causes more deaths than any other cancer of the female reproductive system. An estimated 20,180 new cases of ovarian cancer are expected in the United States this year.

Routine screening for women is limited because, unlike mammograms for breast cancer, there are no sufficiently accurate screening tests currently available. The pelvic examination can only occasionally detect ovarian cancer, generally when the disease is already in advanced stages. However, the combination of a thorough pelvic exam, transvaginal ultrasound and a blood test for the tumor marker CA125 should be offered to women who are at high risk of ovarian cancer.

Promising research conducted at the University of South Florida and the H. Lee Moffitt Cancer Center & Research Institute on a specific protein in the urine may lead to a more sensitive screening test in the future for women with ovarian cancer.

In this pilot study, urinary samples from 18 normal, healthy volunteers, 38 women with benign gynecologic disease and 35 patients in various stages of ovarian cancer were tested for levels of the Bcl-2 protein. The levels of Bcl-2 found in patients with ovarian cancer were ten times higher than that of the healthy volunteers or women with benign disease. Elevated Bcl-2 levels were associated with 92% of ovarian cancers, while blood levels from the CA125 only identified 68% of ovarian cancer patients.

Patricia Kruk, the study’s principal investigator, presented the preliminary findings April 3 at the American Association for Cancer Research meeting in Washington, D.C.

“I am cautiously optimistic”, says Kruk, associate professor of pathology, cell biology and interdisciplinary oncology at USF Health. “We have a long way to go but this is definitely a start.”

Other USF and Moffitt doctors participating in the study include Yira Bermudez, Beatriz Saunders, George Wilbanks and Santo Nicosia as well as members of the Gynecologic Oncology and Cancer Control programs. The team holds a provisional patent for their work with Bcl-2.

The researchers are in the process of requesting funding to conduct clinical trials, thus expanding the sample size and working toward providing a safe, non-invasive, economical detection method for ovarian cancer.

http://hsc.usf.edu/

RELATED STORIES:
Short-term OC use cuts ovarian cancer risk   Experimental Drug Boosts Survival Time For Recurrent Ovarian Cancer   Goodness of milk ‘offset by ovarian cancer risk’   Screening misses early ovarian cancer   Hormone therapy linked to ovarian cancer risk   Birth control pill lowers ovarian cancer risk - study   Researchers Identify Genes Tied to Deadliest Ovarian Cancers   Ovarian cancer screening popular despite guidelines   Research Highlights Important Indicators of Early-stage Ovarian Cancer   4 possible risk factors for ovarian cancer found   New Antibody Offers Hope for Treating Ovarian, Breast Cancer   Correlation Between ChemoFx Assay and Improved Survival in Patients with Ovarian Cancer   New treatment to overpower drug resistance in ovarian cancer   Obesity may raise risk of ovarian cancer   New platinum-phosphate compounds kill ovarian cancer cells   Extracellular protein sensitizes ovarian cancer cells to chemotherapy   St. John’s wort and polymeric nanoparticles to treat ovarian tumors using light   PET/CT scan could be valuable noninvasive tool for determining stages of ovarian cancer   2 studies find new genetic links to ovarian cancer risk   Drinking Tea Associated with Lower Risk of Ovarian Cancer   65% of ovarian cancer cells sideline body’s defences   Study unmasks how ovarian tumors evade immune system

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]